Meeting NewsVideo

VIDEO: Eisai executive highlights key pipeline assets

CHICAGO — Takashi Owa, PhD, chief discovery officer and chief medicine creation officer for Eisai’s oncology business group, spoke with HemOnc Today at ASCO Annual Meeting about the company’s pipeline.

Several of the agents in development are relevant to resistance to current immuno-oncology therapies, Owa said.

“We are very excited about the advancement of these early pipeline assets,” Owa told HemOnc Today.

He also discussed the company’s unique splicing platform, which potentially could lead to the generation of neoantigens.

CHICAGO — Takashi Owa, PhD, chief discovery officer and chief medicine creation officer for Eisai’s oncology business group, spoke with HemOnc Today at ASCO Annual Meeting about the company’s pipeline.

Several of the agents in development are relevant to resistance to current immuno-oncology therapies, Owa said.

“We are very excited about the advancement of these early pipeline assets,” Owa told HemOnc Today.

He also discussed the company’s unique splicing platform, which potentially could lead to the generation of neoantigens.

    See more from ASCO Annual Meeting